It’s a $1.6 trillion question: Which impact investment practices and characteristics truly generate the positive outcomes that investors and stakeholders want to see? With a 21 percent compound annual ...

Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab. Objectives: ...

The EU AI Act is on the verge of becoming the first law to govern the use of artificial intelligence on European level. In light of the extensive set of new obligations imposed on companies, and ...

Managing system risk is paramount for organizations to protect their data and ensure operational continuity. Security Impact Analysis (SIA) is a critical component of this process, offering a ...

The introduction of lebrikizumab, a novel monoclonal antibody targeting interleukin-13 for severe atopic dermatitis (AD), was associated with cost savings of approximately €3.3 million over 3 years ...